Levels of active tyrosine kinase receptor determine the tumor response to Zalypsis

BACKGROUND: Zalypsis® is a marine compound in phase II clinical trials for multiple myeloma, cervical and endometrial cancer, and Ewing’s sarcoma. However, the determinants of the response to Zalypsis are not well known. The identification of biomarkers for Zalypsis activity would also contribute to...

Descripción completa

Detalles Bibliográficos
Autores principales: Moneo, Victoria, Serelde, Beatriz G, Blanco-Aparicio, Carmen, Diaz-Uriarte, Ramon, Avilés, Pablo, Santamaría, Gemma, Tercero, Juan C, Cuevas, Carmen, Carnero, Amancio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2014
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4023704/
https://www.ncbi.nlm.nih.gov/pubmed/24758355
http://dx.doi.org/10.1186/1471-2407-14-281

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4023704/
https://www.ncbi.nlm.nih.gov/pubmed/24758355
http://dx.doi.org/10.1186/1471-2407-14-281

Ejemplares similares